Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy

This clinical feasibility evaluation is intended to further characterize and quantify the potential benefits of the FDA-cleared XR90 Augmented Reality (AR )imaging and guidance platform utilization in percutaneous soft tissue biopsy. This study will seek to build on the findings of safety, procedural benefits, and overall clinical feasibility shown in previous bench, cadaveric, and single-site clinical evaluations.

NCT Number	NCT07046832
Lead Sponsor	MediView XR, Inc.
Conditions	Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma, Biopsy
Enrollment	104 participants
Start Date	2025-06-27
Primary Completion	2027-06 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-02